New Treatment Strategy Offers Hope for Children Too Sensitive for OIT

For children with severe peanut or tree nut allergies, everyday life often involves constant vigilance. Oral immunotherapy (OIT)—a treatment designed to desensitize the immune system by having patients swallow tiny, gradually increasing amounts of an allergen—offers real hope, but it has an important limitation. Some children are so sensitive that they cannot tolerate even the milligram-level amounts of allergen typically required to begin conventional treatment. For these patients, strict avoidance has often remained the only practical option, leaving families with few proactive treatment choices and persistent anxiety about accidental exposure.

A multicenter observational study led by Dr Kyoko Nishikage and published in Allergy, Asthma & Clinical Immunology suggests a promising way around this barrier: an ultra-low-dose induction phase. Designed for children with extremely low reaction thresholds or a history of severe allergic reactions, the approach introduces exceptionally small amounts of an allergen before conventional OIT begins. By starting at doses far below those typically used in treatment, researchers hoped to make OIT accessible to children who previously could not tolerate it.

The study, conducted between 2021 and 2024 at medical centers in Japan, followed 21 children aged 3 to 15 with severe peanut (10 participants) or walnut (11 participants) allergies. Rather than beginning with allergen powders, researchers prepared highly diluted liquid extracts containing protein quantities in the picogram-to-nanogram range. Children took carefully measured doses twice daily at home, following instructions from their medical teams. At approximately monthly clinical visits, physicians gradually increased the dose volume and extract concentration as tolerated. The process continued until participants could transition to conventional OIT using milligram-level amounts of allergen powder.

The results were encouraging. All 10 children with peanut allergies (100%) and 10 of the 11 children with walnut allergies (90.9%) successfully transitioned to conventional OIT. The median time required to reach this milestone was 16 months for the peanut group and eight months for the walnut group. Some children progressed further, with 30% of peanut-allergic participants and 27.3% of walnut-allergic participants reaching the point of consuming commercial food products containing their respective allergens. Importantly, these achievements did not mean the children had outgrown their allergies or could safely consume unrestricted amounts of peanuts or walnuts.

Safety was a central focus of the study, and the findings were promising, although the small number of participants limits conclusions about the treatment’s overall safety. During twice-daily home maintenance dosing, adverse reactions occurred with just 0.02% of administered peanut doses and 0.09% of walnut doses. Reactions were more frequent during medically supervised dose increases, but most were mild to moderate, and no participant required epinephrine during the treatment protocol. These results suggest that beginning with extremely small doses may offer a manageable approach for highly sensitive children when administered under specialized medical supervision.

Researchers also observed changes in allergy-related measurements, including skin-prick test reactions and allergen-specific IgE levels, consistent with reduced allergic sensitivity. Beyond these clinical findings, the approach could offer meaningful psychological benefits. For families who live with constant concern about accidental exposure, increasing the amount of allergen a child can tolerate may help reduce anxiety and improve quality of life. However, the study did not directly establish improvements in psychological well-being or demonstrate that accidental exposures would be safe. Even children undergoing successful OIT can experience anaphylaxis and must continue following their prescribed allergy management plans.

Despite the encouraging results, important questions remain. The study included only 21 children and had no randomized control group, making it difficult to determine how much of the improvement was attributable specifically to the ultra-low-dose approach. Larger, controlled studies will be needed to confirm its effectiveness and safety, determine which patients are most likely to benefit, and establish standardized methods for preparing and administering allergen extracts.

Nevertheless, the findings represent a potentially important advance for children with exceptionally severe nut allergies. By introducing allergens at doses far below those used in conventional treatment, researchers may have found a way to help highly sensitive patients begin OIT when they previously had few options beyond avoidance. While the technique remains investigational and should never be attempted without specialist supervision, it offers an encouraging path toward making food allergy treatment accessible to more children.